Initial results from the ANTLER phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) demonstrated a 100% overall response rate and 80% complete response rate in cohort 1 (n=5 evaluable).
The National Comprehensive Cancer Network added a prostate cancer test, IsoPSA, to its guidelines for early detection of the disease.
The American Society for Radiation Oncology issued an updated clinical guideline on the use of radiation therapy to treat patients with brain metastases, with the goal of supporting the multidisciplinary planning and delivery of advanced radiation therapy techniques to manage intact and resected brain metastases from non-hematologic solid tumors.
Cancer Research UK and the Stichting Oncode Institute, an independent research institute in the Netherlands, formed a strategic alliance focused on translating cancer research into benefits for patients.
RaySearch Laboratories AB and GE Healthcare said they are aiming to develop a radiation therapy simulation and treatment planning workflow solution. The companies said they plan on combining RaySearch’s advanced treatment planning system RayStation with GE Healthcare’s leading multi-modality (CT/MR/molecular imaging) simulator systems.
BridgeBio Pharma and Bristol Myers Squibb announced an exclusive license to develop and commercialize BBP-398, an SHP2 inhibitor, in oncology.
Cullinan Oncology Inc. and Taiho Pharmaceutical Co., Ltd. announced an agreement through which Taiho will acquire Cullinan Pearl Corp. and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417, an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations, while sparing cells expressing wild-type EGFR in non-small cell lung cancer.
Before any strategy can be formulated for next year’s appropriations, cancer groups must confront the formidable challenge of figuring out how much of President Joe Biden’s vision for cancer research is realistic.
In the trenches on the medicine wards and smoking cessation clinics at Parkland Hospital and UT Southwestern Simmons Cancer Center, I see firsthand the increased prevalence of smoking in the Black population, their frequent use of menthol, and the ravaging toll it takes on their health.
Deaths from uterine cancer are rising in the U.S., and are highest among non-Hispanic Black women, according to a new study led by researchers at NCI. The higher death rates are related to the rising incidence of aggressive subtypes of uterine cancer.
